- This event has passed.
Virtual Seminar: Luca Maini, Industrial Organization and Health Economics, Department of Economics, UNC
September 29, 2020 @ 3:45 am - 5:00 am
Biosimilar Entry and the Pricing of Biologic Drugs: 10 Years of the BPCIA
ZOOM DETAILS
https://zoom.us/j/92329528520?pwd=UHplMXBQSEJYYWRxRXFTMVZZVWtvUT09
Meeting ID: 923 2952 8520
Passcode: 698608
The passage of the Biologics Price Competition and Innovation Act (BPCIA) in 2010 was greeted with some degree of skepticism. Relative to generic drugs, biosimilars face many obstacles: larger manufacturing and development costs; higher risk of litigation; and a relative lack of regulation promoting preferential use. As the BPCIA turns 10 years old, we look at how biosimilar entry has affected the price, volume sold, and formulary placement of biologic drugs. Perhaps surprisingly, we find that biologics with an active biosimilar competitor have seen sizeable drops in net (but not list) price, volume sold, and formulary placement. The effects are comparable to the impact of generic drugs before the implementation of mandatory generic substitution laws.
The Cancer Outcomes Research Program Virtual Seminar Series is organized by Drs. Ethan Basch, Stephanie Wheeler, and Matthew Nielsen. Please log into the Zoom meeting between 7:45 am and 8:00 am to help us take attendance prior to the meeting so we can start on time.